Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Immunology | Hematology
Disease Category: Non-Hodgkin's Lymphoma
Location: United States, WV
MEDI-551-1088 - A Phase 2 Randomized Open-Label Study of MEDI-551 in Adults with Relapsed or Refractory Diffused Large B-Cell Lymphoma
Objective - overall response rate, including partial response and complete responsem of subjects trated with MEDI-551 when used in combination with a chemotherapy regimen containing either ifosfamide, carboplatin, and etoposide (ICE) or dexamethasone cytarabine, and cisplatin (DHAP) versus rituximab in combination with ICE or DHAP in subjects with relapsed or refractory diffuse large B-cell lymphoma
Patient Inclusion Criteria: See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.
Patient Exclusion Criteria: See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.
West Virginia University - Clinical Trials Research Unit
PO Box 9260
Morgantown, WV 26506
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these